Research brief
Guardant Health closed at $160.1 on 10 July, down 4.7% for the week but still up 21.6% over four weeks and 77.1% over 12 weeks. The stock sits 47.7% above its weekly Trend Line and 208.4% above Sharemaestro Fair Value, with the latest close 8.1% below its 52-week high. The setup is constructive but stretched, with positive activity pressure, positive Relative Strength and a five-week active Trend Signal offset by a weaker latest sector rank and average-plus, not heavy, volume.
- GH fell 4.7% in the latest week to $160.1, but the broader move remains strong with a 77.1% 12-week return and a 218.5% 52-week gain.
- The weekly Trend Signal is active, with price 47.7% above the $108.4 Trend Line and active trend breadth across 40 of the past 52 weeks.
- Volume was 13.8M shares, equal to 1.1x the 13-week average and 1.2x the 52-week average, confirming participation only modestly.
- Healthcare was weak on the week, down 1.8% on average, while Diagnostics & Research was slightly positive at 0.2%; GH lagged both over the latest week but ranked second in each group over 12 weeks.
- The main risk is extension: the stock is in the top decile of its 52-week range, 208.4% above Fair Value, and recent smart-money readings include six reversal markers.
Weekly price action cools, but the larger move is intact
Guardant Health gave back 4.7% in the latest completed week, closing at $160.1 after reaching a 52-week high of $174.1. That leaves the stock 8.1% below its high but still at 89.5% of its one-year range, a high-range position that keeps the chart constructive while making short-term pullbacks more consequential.
The bigger momentum profile remains unusually strong. GH is up 21.6% over four weeks, 77.1% over 12 weeks, 45.3% over 26 weeks and 218.5% over 52 weeks. The latest pullback therefore looks more like a test of urgency than a regime break, although the negative week weakens the immediacy of the move.
Trend Signal stays active, valuation distance is the tension point
Sharemaestro’s weekly Trend Signal remains active with a five-week active streak and 40 active weeks across the past year, or 76.9% trend breadth. Price is 47.7% above the $108.4 Trend Line, which keeps the weekly regime positive and leaves a meaningful cushion before the core trend level comes into view.
The stretched side of the evidence is the valuation gap. GH trades 208.4% above Sharemaestro Fair Value of $51.89, showing strong premium demand but also raising the bar for fresh confirmation. The setup signature is therefore balanced: trend and momentum are supportive, but the stock is no longer early in the move.
Sector and industry context is supportive over months, mixed over one week
Within US Healthcare, GH’s latest week ranked poorly as the sector fell 1.8% on average and the stock lost 4.7%. The relative picture improves sharply on longer time frames: Healthcare’s average 12-week return was 6.4%, while GH delivered 77.1%, ranking second in the sector group. Sector breadth is not broad, with only 44.0% active trend signals and 36.0% positive Relative Strength breadth, even as Market Dynamics breadth is healthier at 68.0%.
The Diagnostics & Research industry shows a similar split. The group was slightly positive on the week at 0.2% and up 15.2% over 12 weeks, but GH’s 77.1% 12-week return again ranked second. Industry participation is uneven: Market Dynamics breadth is strong at 82.2%, while active trend breadth is 37.8% and Relative Strength breadth is only 28.9%. Peers such as Personalis and Biodesix have also posted large four-week moves, placing GH in a strong but competitive diagnostics momentum cluster.
Volume confirms interest, not a full breakout impulse
Latest volume was 13.8M shares, above the 13-week average of 12.8M and the 52-week average of 11.8M. The resulting 1.1x 13-week volume ratio is constructive enough to show participation, but it is short of the heavier threshold that would make the latest move more convincing after such a large run.
The volume sequence matters. The 26 June advance of 13.2% came on 28.6M shares, followed by a 12.6% gain on 16.3M shares on 3 July. The latest 4.7% decline came on 13.8M shares, still above average but below the prior spike. That pattern suggests buyers have been active, while last week’s selling did not yet show panic-level distribution.
What to watch next
The key test is whether activity pressure can stay positive after the first down week following the late-June acceleration. The latest activity-pressure reading is 1.29 and Relative Strength is 50.28, both constructive, but the expectancy read is Undecided at 48.67%, which fits the mixed short-term evidence.
Risk remains two-sided. Recent weekly-return volatility is 8.6%, below the 52-week level of 9.3%, and the one-year up/down split is favourable at 29 positive weeks versus 23 negative weeks. Still, six reversal markers in the recent smart-money tape, a 208.4% Fair Value premium and weaker latest-week sector rank mean the next advance would need better breadth or a stronger volume ratio, particularly above 1.5x, to improve confirmation.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/guardant-health-77-quarter-diagnostics-fair-value-gap/.
Media and research systems can follow the RSS feed or JSON feed.